organisation · intermediate · partly written
BenevolentAI
BenevolentAI is a company whose proprietary biomedical knowledge graph flagged baricitinib for 2019-nCoV in a company-authored letter.
What it claimed, and what is its own claim more
The Lancet letter, whose authors apart from one are company employees, reports that of 378 AAK1 inhibitors in the graph, 47 were approved and six had high affinity, with baricitinib the only non-oncology one, and says it is not medical advice. This is the company's claim about its own graph and it was not independently tested here. Whether a literature search would have found baricitinib is untested. 1
Reported, not yet replicated
Offers
Knowledge-graph target and repurposing hypotheses
Proprietary graph used to propose drugs for repurposing; documented here only through one company-authored letter. 1
Reported, not yet replicated
Caveats
Company claims about its own graph are not independently tested; no vendor documentation was opened. 1
Reported, not yet replicated
Still open here
- What does the company document publicly about how its graph is built? No vendor documentation, patent or filing was opened.
- The later trial figures for baricitinib could not be opened and are unverified.
Not yet written: URL.
Linked from
Sources
- Richardson P, et al.. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet (2020). paper; opened 2026-11-18 all records citing this
Where it sits on the map
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Kind
- company
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/organisations/benevolentai.json